A recent study has identified a variant of the SLC9A9 gene that is associated with the clinical response to IFN-β treatment. IFN-β induces SLC9A9 expression, resulting in inhibition of proinflammatory T lymphocytes. The findings suggest a key role for this gene in determining the response to IFN-β in patients with multiple sclerosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sørensen, P. S. New management algorithms in multiple sclerosis. Curr. Opin. Neurol. 27, 246–259 (2014).
Rudick, R. A. & Polman, C. H. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 8, 545–559 (2009).
Esposito, F. et al. A pharmacogenetic study implicates SLC9A9 in multiple sclerosis disease activity. Ann. Neurol. http://dx.doi.org/10.1002/ana.24429.
Pappas, D. J. & Oksenberg, J. R. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 74 (Suppl. 1), S62–S69 (2010).
Byun, E. et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch. Neurol. 65, 337–344 (2008).
Comabella, M. et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch. Neurol. 66, 972–978 (2009).
Sellebjerg, F., Søndergaard, H. B., Koch-Henriksen, N., Sørensen, P. S. & Oturai, A. B. Prediction of response to interferon therapy in multiple sclerosis. Acta Neurol. Scand. 130, 268–275 (2014).
Ottoboni, L. et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci. Transl. Med. 4, 153ra131 (2012).
Ohgaki, R., van IJzendoorn, S. C., Matsushita, M., Hoekstra, D. & Kanazawa, H. Organellar Na+/H+ exchangers: novel players in organelle pH regulation and their emerging functions. Biochemistry 50, 443–450 (2011).
Huffman, J. E. et al. Polymorphisms in B3GAT1, SLC9A9 and MGAT5 are associated with variation within the human plasma N-glycome of 3533 European adults. Hum. Mol. Genet. 20, 5000–5011 (2011).
Acknowledgements
F.S. and A.B.O. are supported by grants from the Danish Multiple Sclerosis Society, the Johnson Foundation, and the Warwara Larsen Foundation.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
F.S. has served on scientific advisory boards for Biogen, Genzyme, Merck Serono, Novartis and Teva, has served as a consultant for Biogen Idec and Lundbeck, has received support for congress participation from Biogen Idec, Novartis and Teva, and has received speaker honoraria from Biogen, Genzyme, Merck Serono and Novartis. His laboratory has received research support from Biogen, EMD Serono and Novartis. A.B.O. has served on scientific advisory boards for Novartis, and has received speaker honoraria from Biogen Idec, Merck Serono and Novartis.
Rights and permissions
About this article
Cite this article
Sellebjerg, F., Oturai, A. A clinically useful genetic variant in multiple sclerosis?. Nat Rev Neurol 11, 371–372 (2015). https://doi.org/10.1038/nrneurol.2015.103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.103
